IP Library › Granted Patent US 12,258,339
Granted Patent B2
US 12,258,339 · App. 17/678,782 · Granted Mar 25, 2025

Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer

Inventors: John W. Babich (New York, NY); Justin Wilson (Ithaca, NY); Nikki Thiele (Brooktondale, NY); James Kelly (New York, NY); Shashikanth Ponnala (Ithaca, NY)
Assignee: Cornell University
C07D413/14A61K51/0463A61K51/0482A61K51/1072A61K45/06C07B59/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,339
App. No.
17/678,782
Granted
Mar 25, 2025
Kind
B2
Abstract

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof, wherein M 1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.

Claims (2)

1. A compound of formula

or pharmaceutically acceptable salt thereof.

Continuity (5)
Division 16689856 · Nov 20, 2019
Provisional Application 62769989 · Nov 20, 2018
Provisional Application 62788700 · Jan 4, 2019
Provisional Application 62792835 · Jan 15, 2019
Related Publication 20220185803A1 · Jun 16, 2022
References Cited (138)
US 5162504A · Horoszewicz · 1992 [cited by applicant]
US 5595721A · Kaminski et al. · 1997 [cited by applicant]
US 5736137A · Anderson et al. · 1998 [cited by applicant]
US 5773001A · Hamann et al. · 1998 [cited by applicant]
US 5776456A · Anderson et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5843398A · Kaminski et al. · 1998 [cited by applicant]
US 5846534A · Waldmann et al. · 1998 [cited by applicant]
US 6015542A · Kaminski et al. · 2000 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6090365A · Kaminski et al. · 2000 [cited by applicant]
US 6217866B1 · Schlessinger et al. · 2001 [cited by applicant]
US 6235883B1 · Jakobovits et al. · 2001 [cited by applicant]
US 6287537B1 · Kaminski et al. · 2001 [cited by applicant]
US 6506883B2 · Meteo de Acosta del Rio et al. · 2003 [cited by applicant]
US 6565827B1 · Kaminski et al. · 2003 [cited by applicant]
US 6569430B1 · Waldmann et al. · 2003 [cited by applicant]
US 6602684B1 · Umana et al. · 2003 [cited by applicant]
US 6740522B2 · Anderson · 2004 [cited by applicant]
US 6984720B1 · Korman et al. · 2006 [cited by applicant]
US 6989145B2 · Shitara et al. · 2006 [cited by applicant]
US 7070959B1 · Papadopoulos et al. · 2006 [cited by applicant]
US 7090843B1 · Francisco et al. · 2006 [cited by applicant]
US 7097840B2 · Erickson et al. · 2006 [cited by applicant]
US 7112324B1 · Dorken et al. · 2006 [cited by applicant]
US 7138501B2 · Ruben et al. · 2006 [cited by applicant]
US 7432357B2 · Gillies · 2008 [cited by applicant]
US 7498414B2 · Zhu · 2009 [cited by applicant]
US 7598350B2 · Liu et al. · 2009 [cited by applicant]
US 7612182B2 · Giles-Komar et al. · 2009 [cited by applicant]
US 7638605B2 · Ludwig · 2009 [cited by applicant]
US 7709610B2 · Williams et al. · 2010 [cited by applicant]
US 7829531B2 · Senter et al. · 2010 [cited by applicant]
US 7829673B2 · De Weers et al. · 2010 [cited by applicant]
US 7862817B2 · Adams et al. · 2011 [cited by applicant]
US 7968093B2 · Ludwig · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8128929B2 · Loizos et al. · 2012 [cited by applicant]
US 8153768B2 · Kunz et al. · 2012 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8466263B2 · Marasco et al. · 2013 [cited by applicant]
US 8529902B2 · Teeling et al. · 2013 [cited by applicant]
US 8663638B2 · Lindhofer et al. · 2014 [cited by applicant]
US 8779108B2 · Queva et al. · 2014 [cited by applicant]
US 8809502B2 · Pastan et al. · 2014 [cited by applicant]
US 8921528B2 · Holt et al. · 2014 [cited by applicant]
US 9017676B2 · Lindhofer · 2015 [cited by applicant]
US 9624298B2 · Nostri et al. · 2017 [cited by applicant]
US 9987500B2 · Papadopoulos et al. · 2018 [cited by applicant]
US 10806806B2 · Babich et al. · 2020 [cited by applicant]
US 11285227B2 · Babich et al. · 2022 [cited by applicant]
US 11400165B2 · Krantz et al. · 2022 [cited by applicant]
US 11576986B2 · Salter et al. · 2023 [cited by applicant]
US 20040001835A1 · Woessner et al. · 2004 [cited by applicant]
US 20130309234A1 · Lindhofer · 2013 [cited by applicant]
US 20150064185A1 · Holt et al. · 2015 [cited by applicant]
US 20170326261A1 · Oukhatar et al. · 2017 [cited by applicant]
US 20200353105A1 · Salter et al. · 2020 [cited by applicant]
US 20210121584A1 · Babich et al. · 2021 [cited by applicant]
US 20210236667A1 · Fonge et al. · 2021 [cited by applicant]
US 20220143228A1 · Ludwig et al. · 2022 [cited by applicant]
US 20220143231A1 · Salter et al. · 2022 [cited by applicant]
US 20220184217A1 · White et al. · 2022 [cited by applicant]
US 20230011134A1 · Salter et al. · 2023 [cited by applicant]
US 20230044430A1 · Krantz et al. · 2023 [cited by applicant]
US 20230114130A1 · Babich et al. · 2023 [cited by applicant]
US 20230122503A1 · Goldberg, et al. · 2023 [cited by applicant]
AU 2018249559 · 2019 [cited by applicant]
CA 3058663A1 · 2018 [cited by applicant]
CA 3070610A1 · 2021 [cited by applicant]
CN 110612126A · 2019 [cited by applicant]
EP 3609541A1 · 2020 [cited by applicant]
JP 2020516611A · 2020 [cited by applicant]
KR 20190129931A · 2019 [cited by applicant]
WO WO2018187631A1 · 2018 [cited by applicant]
WO WO2018183906A1 · 2018 [cited by examiner]
WO WO2022162210A1 · 2022 [cited by applicant]
WO WO2022162549A2 · 2022 [cited by applicant]
WO WO2023026235A1 · 2023 [cited by applicant]
WO WO2023049963A1 · 2023 [cited by applicant]
WO WO2023084396A1 · 2023 [cited by applicant]
WO WO2023084397A1 · 2023 [cited by applicant]
Abou, et al., “Towards the stable chelation of radium for biomedical applications with an 18-membered macrocyclic ligand,” Chemical Science, vol. 12, pp. 3733-3742 (2021). [cited by applicant]
Aluicio-Sarduy, et al., “Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications,” Chemistry A European Journal Communication, vol. 26, pp. 1238-1242 (2020). [cited by applicant]
Bobba, et al., “Influence of short PEG linkers on biodistribution of 225AC-Macropa-YS5, an immunoconjugate for treating CD46 expressing cancer,” Abstracts/Nuclear Medicine and Biology, pp. 108-109 (2022). [cited by applicant]
Macropa-NCS Cat. No. HY-111605, Master of Bioactive Molecules, Aug. 2023, 3 pages. [cited by applicant]
Randhawa, et al., “Development of novel sulfur-rich ligands for incorporation into mercury-197m/g radiopharmaceuticals,” Abstracts/Nuclear Medicine and Biology, pp. 108-109 (2022). [cited by applicant]
Reissig, et al., “Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin,” Theranostics, vol. 12, No. 17, pp. 7203-7215 (2022). [cited by applicant]
Shalgunov, et al., “Radiolabeling of a polypeptide polymer for intratumoral delivery of alpha-particle emitter, 225AC, and beta-particle emitter, 177Lu,” Nuclear Medicine and Biology, vol. 104-105, pp. 11-21 (2022). [cited by applicant]
Siwowska, et al., “Preclinical Comparison of Albumin-Binding Radiofolates: Impact of Linker Entities on the In Vitro and In Vivo Properties,” [cited by applicant]
Barrett, et al., “First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer,” J. Nucl. Med.,, vol. 54, 380-387 (2013). [cited by applicant]
Beyer, et al., Comparison of the Blodistribution of [cited by applicant]
Chamas, et al., “Clicked dipicolinic antennae for lanthanide luminescent probes,” Dalton Trans., vol. 39, pp. 7091-7097 (2010). [cited by applicant]
Corson, et al., “Efficient Multigram Synthesis of the Bifunctional Chelating Agent (S)-1-p-Isothiocyanatobenzyl-diethylenetetraminepentaacetic Acid,” Bioconjug. Chem., vol. 11, pp. 292-299 (2000). [cited by applicant]
Crawford, et al., “ [cited by applicant]
Davis, et al., “Comparison of [cited by applicant]
Deal, et al., “Improved in Vivo Stability of Actinium- [cited by applicant]
Dennis, et al., “Albumin binding as a General Strategy for Improving the Pharmacokinetics of Proteins,” J. Biol. Chem., vol. 277, pp. 35035-35043 (2002). [cited by applicant]
Dolomanov, et al., “OLEX2: a Complete Structure Solution, Refinement and Analysis Program,” J. Appl. Crystallogr., vol. 42, pp. 339-341 (2009). [cited by applicant]
Dumelin, et al., “A Portable Albumin Binder form a DNA-Encoded Chemical Library,” Angew. Chem. Int. Ed., 47, 3196-3201 (2008). [cited by applicant]
Ferreirós-Martínez, “Macrocyclic Receptor Showing Extremely High Sr(II)/Ca(II) and Pb(II)/Ca(II) Selectivities with Potential Application in Chelation Treatment of Metal Intoxication,” Inorg. Chem., vol. 50, pp. 3772-37… [cited by applicant]
Ferrier, et al., “Synthesis and Characterization of the Actinium Aquo Ion,” ACS Cent. Sci., vol. 3, pp. 176-185 (2017). [cited by applicant]
Ferrier, et al., “Spectroscopic and computational investigation of actinium coordination chemistry,” Nat. Commun. 2016, 7, 12312 (2016), 8 pages. [cited by applicant]
Gatto, et al., “Synthesis of Calcium-Selective, Substituted Diaza-Crown Ethers: A Novel, One-Step Formation of Bibracchial Lariat Ethers (BiBLEs),” J. Am. Chem. Soc., vol. 106, 8240-8244 (1984). [cited by applicant]
Ghosh, et al., “Tumor Target Prostate Specific Membrane Antigen (PSMA) and Its Regulation in Prostate Cancer,” J. Cell. Biochem., vol. 91, pp. 528-539 (Feb. 2004). [cited by applicant]
Hillier, et al., “Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer,” Cancer Res., vol. 69, pp. 6932-… [cited by applicant]
Jensen, “Aqueous Complexes for Efficient Size-based Separation of Americium from Curium,” Inorg. Chem., vol. 53, pp. 6003-6012 (2014). [cited by applicant]
Kelly, Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imagingA. Amor-Coarasa, A. Nikolopoulou, D. Kim, C. Williams, S. Ponnala, J. … [cited by applicant]
Kozikowski, et al., Design of Remarkably Simply, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase), J. Med. Chem., vol. 44, pp. 298-301 (2001). [cited by applicant]
Leveque, et al., “Clinical Pharmacology of Trastuzumab,” Curr. Clin. Pharmacol., vol. 3, pp. 51-55 (2008). [cited by applicant]
Leyland-Jones, et al., Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel, J. Clin. Oncol., vol. 21, pp. 3965-3971 (Sep. 2003). [cited by applicant]
Maresca, et al., “A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer.” J. Med. Chem., vol. 52(2), pp. 347-357 (2009). [cited by applicant]
Mato-Iglesias, et al., Lanthanide Complexes Based on a 1,7-Diaza-12-crown-4 Platform Containing Picolinate Pendants: A New Structural Entry for the Design of Magnetic Resonance Imaging Contrast Agents, Inorg. Chem., vol… [cited by applicant]
McDevitt, et al., “Tumor Therapy with Targeted Atomic Nanogenerators,” Science, vol. 294, 1537-1540 (Nov. 2001). [cited by applicant]
Miranda-Hernández, et al., “Theoretical approximations and experimental extinction coefficients of biopharmaceuticals,” Anal. Bioanal. Chem., vol. 408, pp. 1523-1530 (2016). [cited by applicant]
Moasser, “The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene 2007, 26, 6469. [cited by applicant]
Müller, “Practice suggestions for better crystal structures,” Crystallogr. Rev., vol. 15, pp. 57-83 (2009). [cited by applicant]
Neil, M. A. Fox, R. Pal, L.-O. Palsson, B. A. O'Sullivan, D. Parker, Dalton Trans., vol. 44, pp. 14937-14951 (2015). [cited by applicant]
Price, et al., “A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal 9Y*,” Nucl. Med. Biol., vol. 43(9), pp. 566-576 (2016). [cited by applicant]
Radchenko, et al., “Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposes,” J. Chromatogr. A, vol. 1380, pp. 55-63 (2015). [cited by applicant]
Roca-Sabio, et al., “Macrocyclic Receptor Exhibiting Unprecedented Selectivity for Light Lanthanides,” J. Am. Chem. Soc., vol. 131, pp. 3331-3341 (2009). [cited by applicant]
Sheldrick, “A short history of SHELX,” Acta Crystallogr. Sect. A , vol. 64, pp. 112-122 (2008). [cited by applicant]
Sheldrick, “SHELXT—Integrated space-group and crystal-structure determination,” Acta Crystallogr. Sect. A, vol. 71, pp. 3-8 (2015). [cited by applicant]
Zatelli, et al., Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds, European Journal of Endocrinology, vol. 156, pp. S29-S35 (2007). [cited by applicant]
Zielinska, et al., “An Improved Method for the Production of Ac-225/Bi-213 from TH-229 for Targeted Alpha Therapy,” Solvent Extr. And Ion Exch., vol. 25, pp. 339-349 (2007). [cited by applicant]
Search Report issued in co-pending European Patent Application No. 18775715.8, dated Oct. 16, 2020. [cited by applicant]
Price, et al., “Matching chelators to radiometals for radiopharmaceuticals”, Chemical Society Reviews, vol. 43, pp. 260-290, (2014). [cited by applicant]
Wilson, et al., “Evaluation of nitrogen-rich macrocyclic ligands 1 chelation of therapeutic bismuth radioisotopes”, Nuclear Medicine and Biology., vol. 42, No. 5, pp. 428-438 (May 2015). [cited by applicant]
International Search Report and Written Opinion Issued in International Application No. PCT/US2019/062479 on Feb. 27, 2020. [cited by applicant]
PUBCHEM. 7,16-Bis (6-carboxy-2-pyridinylmethyl)-1,4, 10, 13-tetraoxa-7, 16-diazacyclooctadecane. Jun. 20, 2012, pp. 1-6 [online], (retrieved on Dec. 27, 2019]. Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.n… [cited by applicant]
Thiele, NA. An Eighteen-Membered Macrocycficligand for Actinium-225TargetedAlphaTherapy. Angewandte Chemie International Edition, vol. 56, pp. 14712-14717 (2017). [cited by applicant]
International Preliminary Report on Patentability issued in International Patent Application No. PCT/US2019/062479, dated Jun. 3, 2021. [cited by applicant]
Wilbur, “Chemical and radiochemical considerations in radiolabeling v [alpha]-emitting radionuclides”, Current Radiopharmaceuticals, Bentham Science Publishers Ltd., NL, vol. 4, No. 3, pp. 214-247 (Jul. 2011). [cited by applicant]
Chen et al., “Novel molecular “add-on” based on Evans Blue confers superior pharmacokinetics and transforms drugs to theranostic agents”, Journal of Nuclear Medicine, vol. 61, 2020, 44 pages. [cited by applicant]
Extended Search Report issued in European Patent Application No. 19887504.9, dated Oct. 5, 2022. [cited by applicant]
Kostelnik et al., “Radioactive Main Group and Rare Earth Metals for Imaging and Therapy”, Chem. Rev., vol. 119, 2019, pp. 902-956. [cited by applicant]
Regueiro-Figueroa et al., “Stabilizing Divalent Europium in Aqueous Solution Using Size-Discrimination and Electrostatic Effects”, Inorg. Chem., vol. 54, 2015, pp. 4940-4952. [cited by applicant]